Using engineered stem cells to repair damaged heart tissue
Engineered Stem Cells for Cardiac Repair
['FUNDING_R01'] · UNIVERSITY OF WASHINGTON · NIH-11047751
This study is exploring how special heart cells made from human stem cells can help heal heart damage after a heart attack, and they're looking at how boosting a certain molecule in these cells might make them even better at improving heart function in animals.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF WASHINGTON (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-11047751 on ClinicalTrials.gov |
What this research studies
This research focuses on developing human stem cell-derived cardiomyocytes (heart muscle cells) as a potential treatment for heart damage caused by myocardial infarction (heart attack). The researchers have successfully differentiated these stem cells into cardiomyocytes that can integrate with existing heart tissue to improve heart function. They are investigating how enhancing the production of a specific nucleotide, dATP, in these engineered cells can further improve their effectiveness in repairing the heart. The study involves testing these cells in animal models to assess their impact on heart recovery.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced a myocardial infarction and have impaired heart function.
Not a fit: Patients with non-cardiac conditions or those who have not experienced a heart attack may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies that significantly improve heart function in patients who have suffered heart attacks.
How similar studies have performed: Previous research has shown promise in using stem cells for cardiac repair, but this specific approach of enhancing dATP production in engineered cells is relatively novel.
Where this research is happening
SEATTLE, UNITED STATES
- UNIVERSITY OF WASHINGTON — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: REGNIER, MICHAEL — UNIVERSITY OF WASHINGTON
- Study coordinator: REGNIER, MICHAEL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.